[Effect of ZHU Lian's type Ⅱ inhibition acupuncture on chronic migraine and serum 5-HT, VEGF, CGRP]

What Was Tested

Researchers studied Calcitonin and CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this randomized controlled trial publication.

Who Took Part

The study group was 120 patients.

A total of 120 patients with chronic migraine were randomized into an observation group (60 cases, 3 cases dropped off) and a control group (60 cases, 2 cases dropped off).

The treatment was given 4 weeks in the two groups.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Calcitonin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In the observation group, ZHU Lian's typeⅡ inhibition acupuncture was applied at Erheliao (TE 22), Shousanli (LI 10), Hegu (LI 4), Yangbai (GB 14), Tongziliao (GB 1), Zusanli (ST 36) ect., once every other day.

Before and after treatment, the migraine clinical symptom score, cerebral hemodynamics indexes (blood flow velocity of arterior cerebral artery [ACA], posterior cerebral artery [PCA], bilateral middle cerebral artery [MCA] and basilar artery [BA]), serum related indexes (levels of 5-hydroxytryptamine [5-HT], vascular endothelial growth factor [VEGF] and calcitonin gene-related peptide [CGRP]) and migraine specific quality of life questionnaire (MSQ) score were observed in the two groups, and the clinical effect was evaluated.

What Was Measured

The subject headings attached to it are Acupuncture Therapy, Calcitonin, Calcitonin Gene-Related Peptide, Migraine Disorders, Quality of Life, Serotonin and Vascular Endothelial Growth Factor A.

The authors tagged it with the keywords 5-hydroxytryptamine (5-HT), ZHU Lian's type Ⅱ inhibition acupuncture, calcitonin gene-related peptide (CGRP), chronic migraine and vascular endothelial growth factor (VEGF).

What This Means in Plain Language

The paper is a randomized study of Calcitonin and CGRP (Calcitonin Gene-Related Peptide) in 120 patients in people with migraine.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Zhongguo zhen jiu = Chinese acupuncture & moxibustion), a journal based in China.

More context: the Calcitonin compound page and the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.